Research programme: atherosclerosis therapy - Digital Gene Technologies/RecordatiAlternative Names: Atherosclerosis therapy research programme - Digital Gene Technologies/Recordati
Latest Information Update: 03 Oct 2005
At a glance
- Originator Digital Gene Technologies; Recordati
- Developer Digital Gene Technologies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 03 Oct 2005 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 03 Nov 2003 Suspended - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 15 Feb 2001 New profile